OM Investors Have Opportunity to Lead Outset Medical, Inc. Securities Fraud Lawsuit

Written By Michael Gary Scott






Outset Medical Lawsuit: Investors’ Chance to Take the Reins in a Sea of Securities Fraud

Outset Medical Lawsuit: Investors’ Chance to Take the Reins in a Sea of Securities Fraud

LOS ANGELES, Sept. 13, 2024Investors with substantial losses are being offered a chance like never before to lead the securities fraud class action lawsuit against Outset Medical, Inc. (“Outset Medical” or the “Company”) with the ticker symbol OM.

Class Period: August 1, 2022August 7, 2024
Lead Plaintiff Deadline: October 28, 2024

Should you aspire to become the lead plaintiff in the Outset Medical case, it’s quite simple – share your contact particulars at the designated webpage. Alternatively, reach out to the diligent Charles H. Linehan at GPM via phone at 310-201-9150, Toll-Free at 888-773-9224, or through email at shareholders@glancylaw.com for further enlightenment on your rights.

Throughout the Class Period, defendants supposedly kept investors in the dark – concealing that the Tablo products were marketed for continuous renal replacement therapy, a use not FDA-approved. The allegations also pinpoint a missed disclosure about the imminent submission of an additional 510(k) application for the Tablo products by Outset Medical, amplifying concerns about potential halts in product sales whilst awaiting FDA’s nod for expanded uses. Moreover, the complaint stresses the lack of preparedness within Outset Medical’s sales division to exploit the surge in Tablo sales, consequently painting a bleak picture of future revenue growth. These accumulated factors paint a sketch where defendants’ optimistic portrayals of the Company’s trajectory are nothing short of deception.

Stay in the loop by tracking updates on LinkedIn, Twitter, or Facebook.

See also  Exclusive: Unveiling Metagenomi, Inc. Securities Scandal Exclusive: Unveiling Metagenomi, Inc. Securities Scandal

If you wish to engage in the class action lawsuit, you are under no obligation to act immediately; you may opt to secure legal counsel of your choosing or observe from the sidelines as a passive member of the class. For those seeking clarity on this legal matter or wishing to discuss their rights with regard to the pending class action lawsuit, your gateway lies with Charles Linehan, Esquire, of GPM, based at 1925 Century Park East, Suite 2100, Los Angeles, California 90067, reachable at 310-201-9150, Toll-Free at 888-773-9224, via email at shareholders@glancylaw.com, or by browsing www.glancylaw.com. Emails should include your address, telephone number, and quantity of shares purchased.

The legal arena can be a theatrical stage where performances are masterful in some regions due to the ebbs and flows of law and ethics.

Contacts
Glancy Prongay & Murray LLP, Los Angeles, Contact Charles Linehan at 310-201-9150 or 888-773-9224, email at shareholders@glancylaw.com, or visit www.glancylaw.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/om-investors-have-opportunity-to-lead-outset-medical-inc-securities-fraud-lawsuit-302248060.html

SOURCE Glancy Prongay & Murray LLP

Market News and Data brought to you by Benzinga APIs